Predicting chemosensitivity to gemcitabine and cisplatin based on gene polymorphisms and mRNA expression in non-small-cell lung cancer cells

Pharmacogenomics

Volumn 16, Issue 1, 2015, Pages 23-34

  Meng, Xiangning ^a   Wang, Geng ^a   Guan, Rongwei ^a   Jia, Xueyuan ^a   Gao, Wei ^a   Wu, Jie ^a   Yu, Jingcui ^a   Liu, Peng ^a   Yu, Yang ^a   Sun, Wenjing ^a   Dong, Haiying ^b   Fu, Songbin ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

chemosensitivity; cisplatin; gemcitabine; non small cell lung cancer; polymorphisms

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; GENOMIC DNA; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; RRM1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ABCB1 GENE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMOSENSITIVITY; CONTROLLED STUDY; ERCC1 GENE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GROWTH INHIBITION; HAPLOTYPE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; LUNG CANCER CELL LINE; MTHFR GENE; MTT ASSAY; NON SMALL CELL LUNG CANCER; PHARMACOGENETICS; REAL TIME POLYMERASE CHAIN REACTION; RRM1 GENE; SEQUENCE ANALYSIS; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; DEOXYCYTIDINE; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); P-GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS;

EID: 84920774478     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.159     Document Type: Article

References (62)

1. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med. 350(4), 351-360 (2004
2. Fossella F, Pereira JR, von Pawel J et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J. Clin. Oncol. 21(16), 3016-3024 (2003
3. Sandler AB, Nemunaitis J, Denham C et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 18(1), 122-130 (2000
4. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 4(4), 307-320 (2005
5. de Laat WL, Jaspers NG, Hoeijmakers JH. Molecular mechanism of nucleotide excision repair. Genes Dev. 13(7), 768-785 (1999
6. Toschi L, Cappuzzo F. Gemcitabine for the treatment of advanced nonsmall cell lung cancer. Onco Targets Ther 2, 209-217 (2009
7. Kwon WS, Rha SY, Choi YH et al. Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet. Genomics 16(6), 429-438 (2006
8. Maring JG, Groen HJ, Wachters FM, Uges DR, de Vries EG. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J. 5(4), 226-243 (2005
9. Sugiyama E, Kaniwa N, Kim SR et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J. Clin. Oncol. 25(1), 32-42 (2007
10. Matakidou A, el Galta R, Webb EL et al. Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Hum. Mol. Genet. 16(19), 2333-2340 (2007
11. Zhou W, Gurubhagavatula S, Liu G et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin. Cancer Res. 10(15), 4939-4943 (2004
12. Lee HW, Choi YW, Han JH et al. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy. Lung Cancer 65(3), 377-382 (2009
13. Li L, Schaid DJ, Fridley BL et al. Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer. Pharmacogenet. Genomics 22(2), 105-116 (2012
14. Pereira S, Fernandes PA, Ramos MJ. Mechanism for ribonucleotide reductase inactivation by the anticancer drug gemcitabine. J. Comput. Chem. 25(10), 1286-1294 (2004
15. Shao J, Zhou B, Chu B, Yen Y. Ribonucleotide reductase inhibitors and future drug design. Curr. Cancer Drug Targets 6(5), 409-431 (2006
16. Perez MA, Cerqueira NM, Fernandes PA, Ramos MJ. Ribonucleotide reductase: a mechanistic portrait of substrate analogues inhibitors. Curr. Med. Chem. 17(26), 2854-2872 (2010
17. Rosell R, Danenberg KD, Alberola V et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 10(4), 1318-1325 (2004
18. Ceppi P, Volante M, Novello S et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann. Oncol. 17(12), 1818-1825 (2006
19. Boukovinas I, Papadaki C, Mendez P et al. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS ONE 3(11), e3695 (2008
20. Bepler G, Kusmartseva I, Sharma S et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J. Clin. Oncol. 24(29), 4731-4737 (2006
21. Bergman AM, Eijk PP, Ruiz Van Haperen VW et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res. 65(20), 9510-9516 (2005
22. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. 64(11), 3761-3766 (2004
23. Oguri T, Achiwa H, Sato S et al. The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity. Mol. Cancer Ther. 5(7), 1800-1806 (2006
24. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N. Engl. J. Med. 356(8), 800-808 (2007
25. Su C, Zhou S, Zhang L et al. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. Med. Oncol. 28(4), 1411-1417 (2011
26. Li F, Sun X, Sun N et al. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am. J. Clin. Oncol. 33(5), 489-494 (2010
27. Han JY, Yoon KA, Park JH et al. DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma. Cancer 117(14), 3201-3208 (2011
28. Sauna ZE, Smith MM, Muller M, Kerr KM, Ambudkar SV. The mechanism of action of multidrug-resistance-linked P-glycoprotein. J. Bioenerg. Biomembr. 33(6), 481-491 (2001
29. Sakaeda T, Nakamura T, Okumura K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol. Pharm. Bull. 25(11), 1391-1400 (2002
30. Takara K, Sakaeda T, Okumura K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr. Pharm. Des. 12(3), 273-286 (2006
31. Stordal B, Hamon M, McEneaney V et al. Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein. PLoS ONE 7(7), e40717 (2012
32. Bergman AM, Pinedo HM, Talianidis I et al. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br. J. Cancer 88(12), 1963-1970 (2003
33. Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J. Natl Cancer Inst. 96(2), 134-144 (2004
34. Alberola V, Sarries C, Rosell R et al. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer. Clin. Lung Cancer 5(6), 360-365 (2004
35. Meng X, Wang G, Liu P et al. ATP-binding cassette B1 gene polymorphisms, mRNA expression and chemosensitivity to paclitaxel in non-small cell lung cancer cells. Respirology 16(8), 1228-1234 (2011
36. Alley MC, Scudiero DA, Monks A et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48(3), 589-601 (1988
37. SNP Analyzer software. http://snp.istech21.com/snpanalyzer/1.2A/
38. National Center for Biotechnology Information (NCBI). www.ncbi.nlm.nih.gov/SNP/
39. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 6(10), 813-823 (2006
40. Kwon WS, Rha SY, Jeung HC et al. G-T haplotype (2677G>T/A and 3435C>T) of ABCB1 gene polymorphisms is associated with ethnic differences to paclitaxel sensitivity in cancer cells with different gene expression pattern. Cancer Lett. 277(2), 155-163 (2009
41. Nief N, Le Morvan V, Robert J. Involvement of gene polymorphisms of thymidylate synthase in gene expression, protein activity and anticancer drug cytotoxicity using the NCI-60 panel. Eur. J. Cancer 43(5), 955-962 (2007
42. Welsh M, Mangravite L, Medina MW et al. Pharmacogenomic discovery using cell-based models. Pharmacol. Rev. 61(4), 413-429 (2009
43. Gazdar AF, Girard L, Lockwood WW, Lam WL, Minna JD. Lung cancer cell lines as tools for biomedical discovery and research. J. Natl Cancer Inst. 102(17), 1310-1321 (2010
44. Simon GR, Begum M, Bepler G. Setting the stage for tailored chemotherapy in the management of non-small cell lung cancer. Future Oncol. 4(1), 51-59 (2008
45. Simon GR, Ismail-Khan R, Bepler G. Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int. J. Biochem. Cell Biol. 39(7-8), 1318-1328 (2007
46. Danzinger S, Filipits M. Biomarkers-The way towards individualized chemotherapy in non-small cell lung cancer (NSCLC). Wien. Med. Wochenschr. 157(21-22), 554-561 (2007
47. Jordheim LP, Seve P, Tredan O, Dumontet C. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol. 12(7), 693-702 (2011
48. Friso S, Choi SW, Girelli D et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc. Natl Acad. Sci. USA 99(8), 5606-5611 (2002
49. Hong W, Wang K, Zhang YP et al. Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population. J. Zhejiang Univ. Sci. B 14(3), 207-215 (2013
50. Bosken CH, Wei Q, Amos CI, Spitz MR. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J. Natl Cancer Inst. 94(14), 1091-1099 (2002
51. Britten RA, Liu D, Tessier A, Hutchison MJ, Murray D. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int. J. Cancer 89(5), 453-457 (2000
52. Arnould S, Hennebelle I, Canal P, Bugat R, Guichard S. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur. J. Cancer 39(1), 112-119 (2003
53. Lord RV, Brabender J, Gandara D et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 8(7), 2286-2291 (2002
54. Cobo M, Isla D, Massuti B et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J. Clin. Oncol. 25(19), 2747-2754 (2007
55. Park SY, Hong YC, Kim JH et al. Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients. Med. Oncol. 23(4), 489-498 (2006
56. Marzolini C, Paus E, Buclin. T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75(1), 13-33 (2004
57. Chaudhary PM, Roninson IB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J. Natl Cancer Inst. 85(8), 632-639 (1993
58. Smith JA, Gaikwad A, Ramondetta LM, Wolf JK, Brown J. Determination of the mechanism of gemcitabine modulation of cisplatin drug resistance in panel of human endometrial cancer cell lines. Gynecol. Oncol. 103(2), 518-522 (2006
59. Yang LY, Trujillo JM, Siciliano MJ, Kido Y, Siddik ZH, Su YZ. Distinct P-glycoprotein expression in two subclones simultaneously selected from a human colon carcinoma cell line by cis-diamminedichloroplatinum (II). Int. J. Cancer 53(3), 478-485 (1993
60. Chen S, Huo X, Lin Y et al. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. Int. J. Hyg. Environ. Health 213(2), 140-145 (2010
61. Wei HB, Lu XS, Shang LH et al. Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis. Arch. Med. Res. 42(5), 412-420 (2011
62. Yin JY, Huang Q, Zhao YC, Zhou HH, Liu ZQ. Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. PLoS ONE 7(6), e38150 (2012).